CR20220104A - Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl - Google Patents

Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl

Info

Publication number
CR20220104A
CR20220104A CR20220104A CR20220104A CR20220104A CR 20220104 A CR20220104 A CR 20220104A CR 20220104 A CR20220104 A CR 20220104A CR 20220104 A CR20220104 A CR 20220104A CR 20220104 A CR20220104 A CR 20220104A
Authority
CR
Costa Rica
Prior art keywords
compounds
hexapirido
oxazin
magl inhibitors
magl
Prior art date
Application number
CR20220104A
Other languages
English (en)
Inventor
Uwe Grether
Bernd Puellmann
Benoit Hornsperger
Joerg Benz
Luca Gobbi
Rainer E Martin
Fionn O`Hara
Bernd Kuhn
Zbinden Katrin Groebke
Martin Ritter
Hans Richter
Carsten Kroll
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67953598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20220104(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220104A publication Critical patent/CR20220104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención proporciona nuevos compuestos heterocíclicos que tienen la Fórmula general (I), en donde A, B, L1 , X, m, n, y R1 a R7 son como se describen en la presente, composiciones que incluyen los compuestos, procesos de elaboración de los compuestos y métodos de uso de los compuestos como inhibidores de monoacilglicerol lipasa (MAGL)
CR20220104A 2019-09-12 2020-09-10 Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl CR20220104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19196879 2019-09-12
PCT/EP2020/075260 WO2021048242A1 (en) 2019-09-12 2020-09-10 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors

Publications (1)

Publication Number Publication Date
CR20220104A true CR20220104A (es) 2022-04-20

Family

ID=67953598

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220104A CR20220104A (es) 2019-09-12 2020-09-10 Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl

Country Status (18)

Country Link
US (1) US11814375B2 (es)
EP (1) EP4028403B1 (es)
JP (1) JP7609854B2 (es)
KR (1) KR20220062515A (es)
CN (1) CN114269755A (es)
AR (1) AR119943A1 (es)
AU (1) AU2020346350A1 (es)
BR (1) BR112022002375A2 (es)
CA (1) CA3151516A1 (es)
CL (1) CL2022000556A1 (es)
CO (1) CO2022001879A2 (es)
CR (1) CR20220104A (es)
IL (1) IL289186A (es)
MX (1) MX2022002311A (es)
PE (1) PE20220565A1 (es)
PH (1) PH12022550339A1 (es)
TW (1) TW202128706A (es)
WO (1) WO2021048242A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
CN111386269A (zh) 2017-11-28 2020-07-07 豪夫迈·罗氏有限公司 新型杂环化合物
EP3737680A1 (en) 2018-01-08 2020-11-18 F. Hoffmann-La Roche AG Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
FI3837263T3 (fi) 2018-08-13 2024-09-03 Hoffmann La Roche Uusia heterosyklisiä yhdisteitä monoasyyliglyserolilipaasin estäjinä
JP7444882B2 (ja) 2018-11-22 2024-03-06 エフ． ホフマン－ラ ロシュ アーゲー 新規の複素環化合物
CA3149096A1 (en) 2019-07-30 2021-02-04 Eikonizo Therapapeutics, Inc. Hdac6 inhibitors and uses thereof
PE20220565A1 (es) 2019-09-12 2022-04-13 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
PH12022551475A1 (en) 2019-12-20 2023-11-29 Tenaya Therapeutics Inc Fluoroalkyl-oxadiazoles and uses thereof
AU2021338497A1 (en) 2020-09-03 2023-02-09 F. Hoffmann-La Roche Ag Heterocyclic compounds
CA3216768A1 (en) 2021-05-04 2022-11-10 Jin Yang 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
AU2022426844A1 (en) 2021-12-29 2024-07-04 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
CN116410483A (zh) * 2023-04-14 2023-07-11 沈阳工业大学 一种羰基联氮杂环超分子鎓盐及其制备方法与应用
CN120040415A (zh) * 2023-11-24 2025-05-27 中国药科大学 一种含喹啉酮骨架的化合物及其应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214038A (en) 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
EP1896453B1 (en) 2005-06-20 2009-12-02 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
AU2007217040A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
WO2007117557A2 (en) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
FR2915199B1 (fr) * 2007-04-18 2010-01-22 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
US8309734B2 (en) 2008-10-29 2012-11-13 Hoffmann-La Roche Inc. Substituted pyridines as GPBAR1 agonists
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
CN103261189B (zh) * 2010-10-22 2015-01-28 詹森药业有限公司 作为单酰基甘油脂肪酶抑制剂的氨基-吡咯烷-氮杂环丁烷二酰胺
AU2012255690B2 (en) 2011-05-16 2015-06-11 Bionomics Limited Amine derivatives as potassium channel blockers
WO2013059118A1 (en) 2011-10-19 2013-04-25 The Trustees Of Columbia University In The City Of New York Cyclopropenimine catalyst compositions and processes
WO2013080156A1 (en) 2011-11-30 2013-06-06 Actelion Pharmaceuticals Ltd 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
PL2794600T3 (pl) 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
SI2800565T1 (sl) 2012-01-06 2020-10-30 Lundbeck La Jolla Research Center, Inc. Karbamatne spojine in metode izdelave in uporabe le-teh
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
BR112015026261A8 (pt) 2013-04-16 2017-12-26 Actelion Pharmaceuticals Ltd Derivados biaromáticos antibacterianos
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
WO2016158956A1 (ja) * 2015-03-30 2016-10-06 武田薬品工業株式会社 複素環化合物
EP3294729A1 (en) 2015-05-13 2018-03-21 Selvita S.A. Substituted quinoxaline derivatives
MX387321B (es) 2015-05-21 2025-03-11 Glaxosmithkline Ip Dev Ltd Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4).
WO2016205590A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
WO2017087863A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2017087858A1 (en) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10323026B2 (en) 2016-03-31 2019-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3438109B1 (en) 2016-03-31 2021-08-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2018228934A1 (en) 2017-06-12 2018-12-20 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as vanin inhibitors
MX2020007318A (es) 2017-09-29 2020-08-24 Takeda Pharmaceuticals Co Compuesto heterociclico.
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
CN111386269A (zh) 2017-11-28 2020-07-07 豪夫迈·罗氏有限公司 新型杂环化合物
TW201930300A (zh) * 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
EP3737680A1 (en) 2018-01-08 2020-11-18 F. Hoffmann-La Roche AG Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
WO2019180185A1 (en) 2018-03-22 2019-09-26 F. Hoffmann-La Roche Ag Oxazine monoacylglycerol lipase (magl) inhibitors
FI3837263T3 (fi) 2018-08-13 2024-09-03 Hoffmann La Roche Uusia heterosyklisiä yhdisteitä monoasyyliglyserolilipaasin estäjinä
CN112469724A (zh) 2018-08-13 2021-03-09 豪夫迈·罗氏有限公司 作为单酰基甘油脂肪酶抑制剂的新型杂环化合物
MA54555A (fr) 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
JP7444882B2 (ja) * 2018-11-22 2024-03-06 エフ． ホフマン－ラ ロシュ アーゲー 新規の複素環化合物
JP7707073B2 (ja) 2019-04-09 2025-07-14 エフ． ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害剤としての複素環式化合物
BR112021026820A2 (pt) 2019-07-03 2022-02-22 Hoffmann La Roche Inibidores heterocíclicos de monoacilglicerol lipase (magl)
PH12021553249A1 (en) 2019-07-09 2023-02-27 Hoffmann La Roche New heterocyclic compounds
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
JP2022548018A (ja) 2019-09-12 2022-11-16 エフ．ホフマン－ラ ロシュ アーゲー 放射性標識化合物
PE20220565A1 (es) 2019-09-12 2022-04-13 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
CA3155161A1 (en) 2019-09-23 2021-04-01 F. Hoffmann-La Roche Ag Heterocyclic compounds
CA3152213A1 (en) 2019-09-24 2021-04-01 F. Hoffmann-La Roche Ag New heterocyclic monoacylglycerol lipase (magl) inhibitors
EP4034602A1 (en) 2019-09-24 2022-08-03 F. Hoffmann-La Roche AG Fluorescent probes for monoacylglycerol lipase (magl)
US20210094972A1 (en) * 2019-09-24 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
AU2021338497A1 (en) 2020-09-03 2023-02-09 F. Hoffmann-La Roche Ag Heterocyclic compounds

Also Published As

Publication number Publication date
WO2021048242A1 (en) 2021-03-18
EP4028403A1 (en) 2022-07-20
MX2022002311A (es) 2022-03-25
TW202128706A (zh) 2021-08-01
CA3151516A1 (en) 2021-03-18
IL289186A (en) 2022-02-01
KR20220062515A (ko) 2022-05-17
JP7609854B2 (ja) 2025-01-07
AU2020346350A1 (en) 2022-02-17
US20210094943A1 (en) 2021-04-01
CN114269755A (zh) 2022-04-01
EP4028403C0 (en) 2023-11-22
PE20220565A1 (es) 2022-04-13
EP4028403B1 (en) 2023-11-22
BR112022002375A2 (pt) 2022-07-19
US11814375B2 (en) 2023-11-14
AR119943A1 (es) 2022-01-19
JP2022548028A (ja) 2022-11-16
CL2022000556A1 (es) 2022-10-21
PH12022550339A1 (en) 2023-03-13
CO2022001879A2 (es) 2022-03-29

Similar Documents

Publication Publication Date Title
CR20220104A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
CO2022002000A2 (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
CO2021002382A2 (es) Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
CL2021000361A1 (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
CO2022002339A2 (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
CO2022002336A2 (es) Compuestos heterocíclicos
MX2020008894A (es) Inhibidores de oxazin monoacilglicerol lipasa (magl).
CR20220116A (es) Compuestos heterocíclicos
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
CR20230115A (es) Compuestos heterocíclicos
CO2023014721A2 (es) Compuestos heterocíclicos
CO2023010212A2 (es) Derivados novedosos de pirimidin-2-il sulfonamida
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
CL2022002661A1 (es) Derivados de benzodiazepinas como pam de gaba a gamma1
CO2017008809A2 (es) Compuestos de benzoxaborol y uso de los mismos
CO2025003011A2 (es) Derivados bicíclicos de tetrahidrotiazepina
UY36662A (es) Compuestos de benzoxaborol y uso de los mismos